Organon reports Q3 adjusted EPS $1.01, consensus 93c

Reports Q3 revenue $1.6B, consensus $1.58B. “I am humbled to be working alongside our talented team during this pivotal time for Organon (OGN),” said Joe Morrissey, Organon’s Interim Chief Executive Officer. “We are harnessing the company’s many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to exercising cost discipline and reducing our debt burden proactively, where possible. These actions will create additional balance sheet capacity, positioning us to pursue future growth opportunities in women’s health and further our mission to deliver impactful medicines and solutions for a healthier every day.”